We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock
DCPH

Delisted

DCPH was delisted on the 10th of June, 2024.

Back to rankings

59 hedge funds and large institutions have $355M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 9

48% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 21

29% more capital invested

Capital invested by funds: $275M → $355M (+$80.3M)

20% more funds holding

Funds holding: 49 → 59 (+10)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
59
Holders Change
+10
Holders Change %
+20.41%
% of All Funds
1.34%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
31
Increased
14
Reduced
9
Closed
21
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$15.3M
2
BlackRock
BlackRock
New York
+$6.94M
3
PC
Polar Capital
United Kingdom
+$4.9M
4
JP Morgan Chase
JP Morgan Chase
New York
+$3.43M
5
SFM
Sphera Funds Management
Israel
+$2.92M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$4.96M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$4.75M
3
OM
Opaleye Management
Massachusetts
-$4.12M
4
FCM
Farallon Capital Management
California
-$1.9M
5
Viking Global Investors
Viking Global Investors
Connecticut
-$1.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Norges Bank
26
Norges Bank
Norway
$1.7M – – –
State Street
27
State Street
Massachusetts
$1.56M +$1.34M +68,681 New
PVI
28
Pura Vida Investments
New York
$1.54M -$36.1K -1,846 -3%
MWNA
29
Marshall Wace North America
New York
$959K +$293K +14,976 +55%
Charles Schwab
30
Charles Schwab
California
$636K +$549K +28,054 New
AllianceBernstein
31
AllianceBernstein
Tennessee
$567K +$490K +25,000 New
Deutsche Bank
32
Deutsche Bank
Germany
$410K +$354K +18,101 New
PPA
33
Parametric Portfolio Associates
Washington
$406K +$350K +17,894 New
Bank of New York Mellon
34
Bank of New York Mellon
New York
$388K +$335K +17,085 New
SSA
35
Schonfeld Strategic Advisors
New York
$340K -$685K -35,000 -70%
TA
36
Teachers Advisors
New York
$332K +$287K +14,655 New
Morgan Stanley
37
Morgan Stanley
New York
$326K +$282K +14,398 New
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$295K +$255K +13,007 New
QSS
39
Quantitative Systematic Strategies
Florida
$288K +$249K +12,724 New
TCIM
40
TIAA CREF Investment Management
New York
$257K +$222K +11,355 New
DCM
41
DAFNA Capital Management
California
$218K -$203K -10,381 -52%
Manulife (Manufacturers Life Insurance)
42
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$179K +$154K +7,863 New
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
$163K +$141K +7,200 New
AIG
44
American International Group
New York
$126K +$109K +5,558 New
UBS Group
45
UBS Group
Switzerland
$100K +$86.3K +4,407 New
SO
46
STRS Ohio
Ohio
$54K +$47K +2,400 New
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$37.3K +$32.2K +1,645 New
Legal & General Group
48
Legal & General Group
United Kingdom
$33K +$28K +1,432 New
Barclays
49
Barclays
United Kingdom
$30K -$464K -23,692 -95%
Parallax Volatility Advisers
50
Parallax Volatility Advisers
California
$30K +$25.5K +1,302 New
1
2
3 4

DCPH Hedge Fund Activity: Q4 2017 in Review

59 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q4 2017, worth a combined $355M — up 29% from $275M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new DCPH positions and 21 closed out — a net gain of 10 holders — while 14 added to existing stakes and 9 trimmed.

The largest buyer was OrbiMed, adding an estimated $15.3M. The largest seller was Citadel Advisors, exiting entirely with an estimated $4.96M sold.

  • 59 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q4 2017, up from 49 in Q3 2017.
  • Funds reported $355M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q4 2017, up 29% quarter-over-quarter.
  • 31 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q4 2017 and 21 closed out, a net change of +10 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q4 2017 was OrbiMed, an estimated $15.3M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q4 2017 was Citadel Advisors, an estimated $4.96M sold.

Based on aggregated 13F filings for Q4 2017.